AstraZeneca finally has some cardiovascular outcomes data it can tout in favor of one of its top diabetes contenders, the long-acting GLP-1 drug Bydureon. But its new results still don’t measure up to data posted by its competitors.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Novo Nordisk A/S (NVO):